ai

Biointron is excited to announce our participation in the 13th Antibody Industrial Symposium (AIS2025), taking place on June 25-26, 2025, at the Palais des Congrès de Tours in Tours, France.

This week, computationally designed antibody therapeutics have been high on the news, leveraging advanced deep learning and AI-driven methodologies to accelerate the discovery and optimization of antibodies.

This year’s Nobel prize in chemistry was awarded last month for using computationally designing novel proteins and predicting structures! The first half of the prize was awarded to John Jumper and Demis Hassabis, who developed AlphaFold, an artificial intelligence (AI) program that can predict a protein’s shape and function from its chemical sequence.

Immunoinformatics merges bioinformatics and immunology. Biointron applies computational tools to accelerate antibody discovery and vaccine development.

Computational antibody design accelerates discovery. Biointron applies AI-driven tools to model, optimize, and improve antibody candidates for therapy.

VHH antibodies, or sdAbs, combine stability and specificity. Biointron explores their camelid origin and their growing role in biotech and medicine.

BIO Asia 2024 in Taiwan featured breakthroughs in biotech and antibodies. Biointron shares key takeaways that define trends in global biologics and innovation.

AET Europe 2024 in London spotlighted antibody innovation. Biointron shares event takeaways on discovery, engineering, and development shaping the therapeutic pipeline.

BIO 2024 in San Diego showcased biotech innovation. Biointron reports highlights on antibody discovery, engineering, and collaborations shaping the future of biologics.

MAGMA-seq is an integrated technology for antibody wide mutational scanning. DOI:10.1038/s41467-024-48072-zThe use of bioinformatics and computational methods were of high interest in several papers published this past week. Protein language models, akin to natural language processing tools, p

Here at the AACR Annual Meeting 2024, there are over 7000 abstracts, 300 poster presentations, and 50 symposia all about cancer research. A few topics that are currently trending in the conference include cancer vaccines, AI for diagnostics, novel immunotherapies, and antibody-drug conjugates (ADCs) as a new modality.

Deep learning brings structural modeling of antibodies to new heights. Explore where it succeeds, where it fails, and hybrid strategies that deliver reliable outcomes.

Harnessing big data in antibody engineering means smarter designs. Explore key databases, their contents, and how to use them to benchmark, compare, and innovate.

Structure modeling platforms from AlphaFold to Rosetta guide smarter antibody design. Learn strengths, caveats, and how to pair predictions with experimental validation.

Deep learning models are redefining antibody research. See how architectures and datasets translate into real-world gains in discovery, screening, and optimization.